Recruitment

Recruitment Status
Completed

Inclusion Criteria

Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements.
Polycystic liver disease with underlying diagnosis of (PCLD or ADPKD), defined as ≥ 20 liver cysts
Symptomatic defined as ECOG-PS ≥ 1 (2), and having at least three out of ten PCLD symptoms:
...
Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements.
Polycystic liver disease with underlying diagnosis of (PCLD or ADPKD), defined as ≥ 20 liver cysts
Symptomatic defined as ECOG-PS ≥ 1 (2), and having at least three out of ten PCLD symptoms:
18 ≤ age ≤ 80 years
Total liver volume ≥ 2500 mL

Exclusion Criteria

Renal dysfunction (MDRD-Glomerular filtration rate< 30 ml/min/1.73m2)
Use of oral anticonceptives or estrogen supplementation
Use of drugs that can interact with UDCA, such as colestyramine, aluminium hydroxide or cyclosporin
...
Renal dysfunction (MDRD-Glomerular filtration rate< 30 ml/min/1.73m2)
Use of oral anticonceptives or estrogen supplementation
Use of drugs that can interact with UDCA, such as colestyramine, aluminium hydroxide or cyclosporin
Use of UDCA in 3 months before baseline
Intervention (aspiration or surgical intervention) within six months before baseline
Inflammation of small intestine or colon
Patients with a kidney transplant
Females who are pregnant or breast-feeding or patients of reproductive potential not employing an effective method of birth control.
Hypersensitivity reaction to UDCA or patients with galactose-intolerance, lactase deficiency or glucose-galactose malabsorption
History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
Acute cholecystitis or frequent biliary colic attacks
Treatment with somatostatin analogues within six months before baseline
Acute stomach or duodenal ulcers
Mental illness that interferes with the patient ability to comply with the protocol
Enrolment in another clinical trial of an investigational agent while participating in this study

Summary

Conditions
  • Polycystic Kidney, Autosomal Dominant
  • Polycystic Liver Disease
  • Polycystic Liver Disease (PLD)
Type
Interventional
Phase
Phase 2
Design
  • Allocation: Randomized
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 80 years
Gender
Both males and females

Description

We investigated whether ursodeoxycholic acid was able to reduce total liver volume in polycystic liver disease.

We investigated whether ursodeoxycholic acid was able to reduce total liver volume in polycystic liver disease.

Inclusion Criteria

Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements.
Polycystic liver disease with underlying diagnosis of (PCLD or ADPKD), defined as ≥ 20 liver cysts
Symptomatic defined as ECOG-PS ≥ 1 (2), and having at least three out of ten PCLD symptoms:
...
Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements.
Polycystic liver disease with underlying diagnosis of (PCLD or ADPKD), defined as ≥ 20 liver cysts
Symptomatic defined as ECOG-PS ≥ 1 (2), and having at least three out of ten PCLD symptoms:
18 ≤ age ≤ 80 years
Total liver volume ≥ 2500 mL

Exclusion Criteria

Renal dysfunction (MDRD-Glomerular filtration rate< 30 ml/min/1.73m2)
Use of oral anticonceptives or estrogen supplementation
Use of drugs that can interact with UDCA, such as colestyramine, aluminium hydroxide or cyclosporin
...
Renal dysfunction (MDRD-Glomerular filtration rate< 30 ml/min/1.73m2)
Use of oral anticonceptives or estrogen supplementation
Use of drugs that can interact with UDCA, such as colestyramine, aluminium hydroxide or cyclosporin
Use of UDCA in 3 months before baseline
Intervention (aspiration or surgical intervention) within six months before baseline
Inflammation of small intestine or colon
Patients with a kidney transplant
Females who are pregnant or breast-feeding or patients of reproductive potential not employing an effective method of birth control.
Hypersensitivity reaction to UDCA or patients with galactose-intolerance, lactase deficiency or glucose-galactose malabsorption
History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
Acute cholecystitis or frequent biliary colic attacks
Treatment with somatostatin analogues within six months before baseline
Acute stomach or duodenal ulcers
Mental illness that interferes with the patient ability to comply with the protocol
Enrolment in another clinical trial of an investigational agent while participating in this study

Tracking Information

NCT #
NCT02021110
Collaborators
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • Biodonostia Health Research Institute
Investigators
  • Principal Investigator: Joost PH Drenth, dr. Radboud University Medical Centre Nijmegen, the Netherlands
  • Joost PH Drenth, dr. Radboud University Medical Centre Nijmegen, the Netherlands